US Patent

US8067427 — Pharmaceutical compositions comprising ZD6474

Formulation · Assigned to AstraZeneca AB · Expires 2028-08-08 · 2y remaining

Vulnerability score 60/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a pharmaceutical composition containing ZD6474, a brittle diluent, and a second diluent with ductile compression properties.

USPTO Abstract

A pharmaceutical composition comprising ZD6474 or a pharmaceutically acceptable salt thereof, a brittle diluent and a second diluent which is practically insoluble and has ductile compression properties.

Drugs covered by this patent

Caprelsa (VANDETANIB) · Sanofi

Patent Metadata

Patent number: US8067427
Jurisdiction: US
Classification: Formulation
Expires: 2028-08-08
Drug substance claim: No
Drug product claim: Yes
Assignee: AstraZeneca AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.